Shanghai Henlius gets CSRC nod for equity issue

By Jonathan Breen
07 Aug 2020

Hong Kong-listed Shanghai Henlius Biotech has won approval from the Mainland securities regulator to sell a chunk of new shares.

The China Securities Regulatory Commission gave the company the greenlight to issue up to 32.7m primary H-shares, according to a statement from the regulator this week. The approval is valid for 12 months.

Shanghai Henlius can sell the stock in installments, but the time between each issuance must ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial